| P2093 | author name string | Jeroen T Buijs | |
| | Henri H Versteeg | |
| P2860 | cites work | Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy | Q24194257 |
| | Deficiency of protein C in congenital thrombotic disease | Q24600822 |
| | IDH1 and IDH2 mutations in gliomas | Q24648948 |
| | Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 |
| | The Significance of Ras Activity in Pancreatic Cancer Initiation | Q26765230 |
| | The widespread regulation of microRNA biogenesis, function and decay | Q28131796 |
| | Prevalence of pulmonary embolism at necropsy in patients with cancer | Q33840286 |
| | Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer | Q33965106 |
| | Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006 | Q34250240 |
| | Mutation in blood coagulation factor V associated with resistance to activated protein C. | Q34340007 |
| | Translating RNA sequencing into clinical diagnostics: opportunities and challenges. | Q34519034 |
| | Genetic alterations and signaling pathways in the evolution of gliomas | Q35001574 |
| | Multilocus genetic risk scores for venous thromboembolism risk assessment | Q35070627 |
| | Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism | Q35266365 |
| | Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets | Q36335932 |
| | Development and validation of a predictive model for chemotherapy-associated thrombosis | Q36657982 |
| | Hypercoagulability and tissue factor gene upregulation in hematologic malignancies | Q37223524 |
| | Epidemiology of cancer-related venous thromboembolism | Q37242472 |
| | Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism | Q37331210 |
| | Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity | Q37381874 |
| | Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. | Q37765683 |
| | New fundamentals in hemostasis | Q38072904 |
| | Epidemiology of cancer-associated venous thrombosis | Q38125997 |
| | Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer? | Q38591731 |
| | Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. | Q39028469 |
| | C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice | Q39060831 |
| | Circulating cell-free microRNAs as clinical cancer biomarkers | Q39266731 |
| | Mutant IDH1 and thrombosis in gliomas. | Q39355644 |
| | Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients | Q39567969 |
| | Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. | Q39704661 |
| | PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. | Q40453813 |
| | Genetic diagnosis of Mendelian disorders via RNA sequencing | Q40953669 |
| | Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer | Q41159101 |
| | Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis | Q42290260 |
| | Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial | Q43284608 |
| | Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis | Q44448101 |
| | Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer | Q44598281 |
| | Malignancies, prothrombotic mutations, and the risk of venous thrombosis | Q45249091 |
| | Absolute quantitation of proteins in human blood by multiplexed multiple reaction monitoring mass spectrometry. | Q45931723 |
| | The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis | Q46443827 |
| | Body height and risk of venous thromboembolism: The Tromsø Study | Q47434717 |
| | Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. | Q47958105 |
| | TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. | Q48009833 |
| | Genes associated with venous thromboembolism in colorectal cancer patients. | Q49787060 |
| | Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. | Q52339910 |
| | The role of podoplanin in cancer-associated thrombosis. | Q52716145 |
| | Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. | Q53142866 |
| | VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. | Q53362939 |
| | Association of deep venous thrombosis with prothrombotic gene polymorphism identified in lung cancer cases | Q54401667 |
| | Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. | Q54571473 |
| | Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. | Q54593956 |
| | Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study. | Q55396746 |
| | Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. | Q55457269 |
| | Cancer-associated thrombosis: The search for the holy grail continues | Q57824763 |
| | Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients-results from the Vienna Cancer And Thrombosis Study (CATS) | Q58955398 |
| | THROMBOPHILIA CAUSED BY INHERITABLE DEFICIENCY OF BLOOD ANTITHROMBIN | Q78230104 |
| | Incidence and mortality of venous thrombosis: a population-based study | Q79969827 |
| | Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients | Q81311961 |
| | Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis | Q81831134 |
| | Trousseau's syndrome - what is the evidence? A population-based autopsy study | Q82769257 |
| | Polymorphisms in the protein C gene as risk factor for venous thrombosis | Q83162671 |
| | Genetic variants associated with deep vein thrombosis: the F11 locus | Q84190583 |
| | Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients | Q86398284 |
| | Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients | Q87379170 |
| | Association of F11 polymorphism rs2289252 with deep vein thrombosis and related phenotypes in population of Latvia | Q87499858 |
| | Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study | Q88494004 |
| | Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer | Q89777016 |
| | The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis | Q90870313 |
| | Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas | Q91859000 |
| | Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis | Q92080263 |
| | Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism | Q92667373 |
| | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer | Q93160371 |
| P304 | page(s) | S43-S49 | |
| P577 | publication date | 2020-07-01 | |
| P1433 | published in | Thrombosis Research | Q15758741 |
| P1476 | title | Genes and proteins associated with the risk for cancer-associated thrombosis | |
| P478 | volume | 191 Suppl 1 | |